Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Nov / Easing Ion-Exchange Chromatography
Manufacture Bioprocessing - Upstream & Downstream Biopharma Sponsored

Easing Ion-Exchange Chromatography

Why salt-tolerant resins make for “happier” biomolecules with better binding.

By Romain Dabre 11/14/2018 0 min read

Sponsored By

Share

Process chromatography is one of the main components of downstream processing. One of the most commonly-used chromatography techniques for the purification of recombinant biomolecules is ion-exchange chromatography. It is, for example, the preferred step after protein A capture for the intermediate purification of antibodies and antibody constructs. Ion-exchange chromatography uses the ionic charges on the surface of the proteins to bind and elute, and requires specific buffer conditions. Often, a desalting or dilution step is required to ensure proper binding of the target to the ion exchanger.

The introduction of salt-tolerant ion-exchange chromatography resins has been appreciated by the industry. Salt tolerant means that the binding of biomolecules will work at higher salt concentrations than on traditional ion exchange. Normally in ion-exchange chromatography, you bind the biomolecule on the column and elute your target by increasing the salt concentration. Typically, that means the feedstock needs to be salt-free before going onto the chromatography steps, adding time and money to the process. With salt-tolerant ion-exchange chromatography resins, you can work with a higher salt concentration for binding, allowing for more straight-forward processes with less steps and/or less dilution while maximizing productivity through high dynamic binding capacity (DBC). For example, the salt-tolerant cation exchanger Toyopearl Sulfate-650F exhibits DBCs up to 120 g/L at salt concentrations as high as 0.3 mol/L. Another example of the unique performances of these resins is the capacity of the salt-tolerant anion exchanger Toyopearl NH2-750F to remove mAb-aggreagtes along with viruses, endotoxins, DNA and HCP, paving the way for reducing the number of steps in antibody purification. 

It is also important to point out that biomolecules are natural structures – and when existing in humans or plants there is always the presence of salt. Being without salt, as required in conventional ion-exchange chromatography, goes against the laws of nature, and some proteins do not like these conditions. In this way, salt-tolerant ion-exchange chromatography has a huge advantage. Although they have only been on the market a few years, our salt-tolerant resins are already being used in phase III pre-commercial manufacturing steps. In some ways, it is remarkable how these resins have made it to this stage so quickly – but there’s a simple reason for the rapid uptake: they solve previously intractable problems. And I would say that they are perfect for newer antibody formats coming through pipelines.

Collaboration works

As Patrick explains, collaboration is very important to us at Tosoh, and we have contact with many companies and research institutes. Yes, we sell our products, but I like to say that our expertise is something that we offer for free! It’s very rewarding that customers see us as experts who they can ask for help when they have a problem with developing methods, or choosing the best material conditions for a specific program. One of our collaborative projects involved the Max-Planck Institute for biochemistry in Martinsried (Germany), one of the largest institutes within the Max Planck Society, and we’re proud to share their feedback: 

Leopold Urich, scientist in the group of Sabine Suppmann (Head Recombinant Protein Production), works in the Institute’s core facility – one of many service facilities devoted to supporting the scientists during their work. Among the many areas of expertise, the Institute is working in the field of “recombinant protein production” – essentially, developing strategies for protein expression and purification. As a result, all of Urich’s projects require some form of chromatography.

Urich described Tosoh’s Toyopearl Sulfate-650F and Toyopearl NH2-750F as breakthroughs for his work because ion-exchange was something the group had been struggling with. “The biggest issue has always been the binding conditions with other ion-exchange resins, meaning very low salt concentrations,” says Urich. “Most of the material we are working with simply can’t withstand such low amounts of salt. This problem has since been eliminated and, on top of that, we’re seeing some great separation results in our testing, even with simple linear gradients especially with the Toyopearl anion exchange columns.”

Tosoh has also worked with Sanofi, and generated more positive feedback. Benoit Mothes, Head of Sanofi’s Global DSP Breakthrough Technologies Skill Center, says, “The Toyopearl NH2-750F anion exchange resin is the greatest innovation from the past 10 years in the downstream processing field.” 

We are always open for collaboration with the industry. If you are interested in working with us, please email: romain.dabre@tosoh.com.

Dr. Romain Dabre is Product Manager, Process Business at Tosoh Bioscience, Germany.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Tosoh, Application Note, “Antibody-Drug Conjugate Mimic Purification with Toyopearl® PPG-600m HIC Resin for DAR-Separation”. Available at https://bit.ly/2PVztWy.

About the Author(s)

Romain Dabre

Romain Dabre is Product Manager, Process Business at Tosoh Bioscience, Germany.

More Articles by Romain Dabre

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Pass Me a Bottle Opener
Bioprocessing - Upstream & Downstream
Pass Me a Bottle Opener

December 1, 2014

0 min read

Upstream processes in biopharma manufacturing are growing ever more efficient; conversely, downstream processing is increasingly a bottleneck. Can a new generation of chromatography techniques and technologies get things moving again?

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Biotech Versus the Superbugs
Bioprocessing - Upstream & Downstream Drug Discovery
Biotech Versus the Superbugs

April 7, 2025

6 min read

Meet one company and its new drug candidate in the fight against gram-negative bacterial infections.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.